FAQ

SYN-004

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
012320142016

Related topics

Related topics

2 relations

Broader (2)

Recombinant Proteinsbeta-Lactamase

Related mentions per year

Related mentions per year

1964-2018
1960198020002020
SYN-004
Recombinant Proteins
beta-Lactamase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
AIM To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic-mediated damage. METHODS AND… (More)
Is this relevant?
2017
2017
Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
SYN-004 (ribaxamase) delayed release drug product is a multi-particulate, hard capsule for oral delivery of a recombinant… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
2017
2017
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
 
Is this relevant?
2016
2016
Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
The gut microbiome, composed of the microflora that inhabit the gastrointestinal tract and their genomes, make up a complex… (More)
Is this relevant?
2016
2016
Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… (More)
Is this relevant?
2016
2016
Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1…
BACKGROUND SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… (More)
Is this relevant?
2014
2014
270SYN-004, a Class A Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora
Background. ß-lactam antibiotics that are excreted into the intestine can damage the microflora, which can lead to serious… (More)
Is this relevant?